Rising Incidence Of Ocular Disorders Fuels Growth In The Ophthalmic Medical Lasers Market: An Emerging Driver Transforming The Ophthalmic Medical Lasers Market Landscape

The Nucleic Acid Based Gene Therapy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Nucleic Acid Based Gene Therapy Market?
The nucleic acid-based gene therapy market has shown strong growth, rising from $0.81 billion in 2024 to $0.88 billion in 2025 at a CAGR of 9.4%. The growth is driven by a better understanding of human genetics, growing demand for personalized medicine, the expanding pipeline of gene therapy products, and increased government support for gene therapy, especially for genetic disorders and cancer therapy.

The nucleic acid based gene therapy market is projected to expand rapidly over the next few years, reaching $1.33 billion in 2029 with a compound annual growth rate (CAGR) of 10.7%. This growth will be supported by increasing indications, greater funding, growing patient advocacy, rising investment in gene therapy R&D, broader application scope, and a focus on rare diseases. Key trends include ex vivo gene editing, progress in in vivo editing, combination therapies, targeted delivery, rare disease applications, and non-viral delivery methods.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2820

What Are the Different Nucleic Acid Based Gene Therapy Market Segments?
The nucleic acid based gene therapy market covered in this report is segmented -

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies
2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases
3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:
1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)
2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies
3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)
4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs
5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes
6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers
7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

What Are the Primary Drivers Shaping the Nucleic Acid Based Gene Therapy Market?
Government and corporate funding is projected to support the nucleic acid-based gene therapy market. These therapies target the genetic basis of diseases like cystic fibrosis, diabetes, and hemophilia, offering the potential for a cure rather than treatment. For instance, the NIH announced in August 2022 that it would invest $34 million annually over five years into HIV research. Such financial support is expected to further drive the nucleic acid-based gene therapy market.

Which Companies Are Leading in the Nucleic Acid Based Gene Therapy Market?
Major companies operating in the nucleic acid based gene therapy market include Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

What Trends Are Expected to Dominate the Nucleic Acid Based Gene Therapy Market in the Next 5 Years?
In March 2023, Moderna, Inc., a biotechnology company based in the US, formed a partnership with Generation Bio. Through this collaboration, Moderna seeks to develop innovative nucleic acid therapies, including those that can target immune cells, to speed up the progress of their respective non-viral genetic medicine pipelines. Moderna will also finance all research and development activities related to this partnership, which includes an upfront payment for research efforts. Generation Bio is a US-based biotechnology firm specializing in nucleic acid-based gene therapies.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

What Are the Top Revenue-Generating Geographies in the Nucleic Acid Based Gene Therapy Market?
North America was the largest region in the nucleic acid-based gene therapy market in 2023. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Nucleic Acid Based Gene Therapy Market?
2. What is the CAGR expected in the Nucleic Acid Based Gene Therapy Market?
3. What Are the Key Innovations Transforming the Nucleic Acid Based Gene Therapy Industry?
4. Which Region Is Leading the Nucleic Acid Based Gene Therapy Market?

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.